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Abstract
Background: High-dose benzodiazepine dependence constitutes a major clinical concern. Although withdrawal
treatment is recommended, it is unsuccessful for a significant proportion of affected patients. More recently, a
benzodiazepine maintenance approach has been suggested as an alternative for patients’ failing discontinuation
treatment. While there is some data supporting its effectiveness, patients’ perceptions of such an intervention have
not been investigated.
Methods: An exploratory qualitative study was conducted among a sample of 41 high-dose benzodiazepine (BZD)-
dependent patients, with long-term use defined as doses equivalent to more than 40 mg diazepam per day and/or
otherwise problematic use, such as mixing substances, dose escalation, recreational use, or obtainment by illegal
means. A qualitative content analysis approach was used to evaluate findings.
Results: Participants generally favored a treatment discontinuation approach with abstinence from BZD as its
ultimate aim, despite repeated failed attempts at withdrawal. A maintenance treatment approach with continued
prescription of a slow-onset, long-acting agonist was viewed ambivalently, with responses ranging from positive
and welcoming to rejection. Three overlapping themes of maintenance treatment were identified: “Only if I can try
to discontinue…and please don’t call it that,” “More stability and less criminal activity…and that is why I would try
it,” and “No cure, no brain and no flash…and thus, just for everybody else!”
Conclusions: Some patients experienced slow-onset, long-acting BZDs as having stabilized their symptoms and
viewed these BZDs as having helped avoid uncontrolled withdrawal and abstain from criminal activity. We
therefore encourage clinicians to consider treatment alternatives if discontinuation strategies fail.
Keywords: Benzodiazepine dependence, Maintenance treatment, Attitudes, Withdrawal, Qualitative, Explorative,
Interview
Background
High-dose benzodiazepine (BZD) dependence is an increas-
ingly recognized clinical problem, and there is ongoing de-
bate about its definition [1, 2] and optimal treatment
strategies [3–6]. This form of dependence is not confined
to users who exceed a set amount of diazepam equivalents,
but is typically found in patients who have a high-dose,
long-term and/or otherwise problematic use, such as
mixing BZDs, escalating dosage, using BZDs for recre-
ational purposes, obtaining them by illegal means, and/or
experiencing negative social consequences [1, 3]. Although
there is some evidence supporting the use of flumazenil
infusions when treating this group [7–9], current guide-
lines favor a gradual discontinuation, with complete ab-
stinence from BZDs as its eventual aim, irrespective of the
abuse patterns mentioned above [10, 11].
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While types of intervention differ (e.g., gradual BZD
reduction, with a long or short half-life BZD, switching
to non-BZD anxiolytics, or prescribing adjunctive medi-
cations such as antidepressants or anticonvulsants), evi-
dence exists that high-dose-dependent individuals, in
particular, are not very successful in completing the
withdrawal treatment or in abstaining from BZD use in
the long term [1, 12–14]. Alternatively, some authors
suggest the investigation of a long-term maintenance or
agonist substitution approach with a slow-onset and
long-acting (= long half-life) BZD for patients who wish
to discontinue high-dose BZD use but find themselves
unable to abstain completely [3, 15]. There is now emer-
ging scientific evidence that a medical intervention ap-
proach, successfully used for years in the treatment of
opioid dependence [16–18], might also have a potential
role in high-dose BZD dependence [2, 19]. A recent
open, naturalistic study was conducted among patients
who were enrolled in a methadone maintenance treat-
ment program and had a comorbid BZD dependence.
The study compared clonazepam detoxification and
clonazepam maintenance treatment and found that
78.8 % of patients in the maintenance group refrained
from abusing additional BZDs after stabilization and
that this rate remained constant for more than an en-
tire year. The authors therefore concluded that a spe-
cific group of high-risk patients with long-term heroin
and BZD dependence and multiple attempts at BZD ab-
stinence might fare better with a maintenance treatment
approach [20].
In previous articles, we reported reasons for the initial
and continued use of benzodiazepines in high doses,
procurement strategies, and factors that motivate high-dose
benzodiazepine-dependent individuals to stop taking these
medications and on how they experienced withdrawal [14,
21]. Here, we expand this work by focusing on the percep-
tions of this group towards BZD discontinuation treatment
versus a BZD maintenance or substitution treatment ap-
proach. This is important, since it is known that patients
generally expect to improve as a result of treatment
and that they are significantly more likely to discontinue
treatment when their treating professionals’ assessments
of appropriate treatment do not meet their expectations of
helpfulness [22, 23]. In studies of opioid maintenance for
example, it was reported that current opioid users “formu-
late shorter-term goals that do not necessarily equate with
complete heroin abstinence” and use “short-term metha-
done episodes as self-prescribed attempts at risk reduc-
tion, and as pilot tests while considering or anticipating
entering treatment to quit the use of illicit drugs” [24].
Patients’ subjective views are of clinical importance be-
cause past research indicates that individuals should be
presented with a variety of treatment alternatives, rather
than simply being informed about what is obtainable
or easiest; in addition, this prior research has found
interventions to be most beneficial when patients are
prepared for what to expect of the “process of care”
(e.g., description of the therapeutic setting in psychother-
apy or discomfort of pharmacological intervention) and of
“outcome” (e.g., clinical improvement or symptom reduc-
tion) [22, 25, 26].
Thus, the objective of the current qualitative study
was to understand both the core convictions and beliefs
surrounding a benzodiazepine maintenance (-agonist)
treatment approach, as well as participants’ openness to
an alternative to the current standard of care withdrawal
treatment with complete abstinence as its aim.
Methods
Design
An exploratory qualitative study was conducted to inves-
tigate the perceptions and views of high-dose BZD-
dependent patients on a BZD maintenance or substitution
treatment strategy.
Research sites
This study was conducted at two different sites of the
Psychiatric University Hospital Zurich. The participants
who were recruited at the outpatient service were inter-
viewed at that location, while participants who were in
inpatient treatment at the time were interviewed in the
hospital. At both sites, interviews were conducted out-
side the regular treatment setting, in private offices, and
in an atmosphere that permitted the participants to
freely and fully express their own views and perceptions.
Instrument development
This choice of framework guided our decision to include
key areas for exploration in line with the study’s aims.
Study domains were discussed and agreed upon in
preparation for the study, and after an extensive litera-
ture review, a topic guide was developed that provided
a flexible interview framework to explore beliefs and
perceptions. Examples of interview questions surrounding a
BZD maintenance or substitution treatment strategy
included: “How would you feel about a substitution (a
replacement) for benzodiazepines? Like, for example,
heroin, that gets substituted with methadone?” Further-
more, we gave specific examples for slow-onset, long-
acting benzodiazepines usually by mentioning specific
brand names. We aimed to make it understandable for
each individual participant that (a) a maintenance treat-
ment intervention would not mean that they would
have to completely withdraw from benzodiazepines and
could potentially be on this substance for a long time
and (b) that they would be switched over to a different
drug formulation that would require them to take this
substance less frequently, create less sedation, and result
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in fewer euphorigenic effects (“no flash”) but (c) would still
belong to the class of benzodiazepines.
In addition, we allowed themes and motifs identified
in earlier interviews to be explored in those that followed
and combined the principles of maximum variation and
complexity reduction to simultaneously widen the scope
of results and the examination of previous assumptions.
Sampling and recruitment
To achieve the aims of the qualitative study, a mixed
method of purposeful sampling and saturation sampling
principles was utilized. The sample was chosen to reflect
diversity in a range of clinical aspects (past treatment
experience, comorbidity, gender) as well as in socio-
economic background (occupational status). Recruitment
of participants by researchers was continued until satur-
ation of data was reached, operationally defined as when
no new themes emerged and we had tested all categories
for disconfirming case variations. To achieve greater vari-
ation of themes and motifs, we recruited subjects from
general treatment settings and from specialized units for
the treatment of substance use disorders.
In total, 60 potential participants were contacted by
the researchers in person: they were at least 18 years of
age; were willing to give their written, informed consent;
and suffered from a high-dose BZD dependence (defined
as any use for an extended period of an equivalent dose
of more than 40 mg diazepam per day and/or otherwise
problematic use of BZDs, such as mixing BZDs, escalating
their dosage, using them for recreational purposes, or
obtaining BZDs by illegal means). Exclusion criteria
were defined as vastly insufficient language skills and/
or acute intoxication. Each patient’s chart, including a
complete biographical and psychiatric history and diag-
nosis according to ICD-10, was made available to us by
the clinic. Nineteen individuals declined to participate,
and 41 individuals who met our criteria were then
interviewed between 2011 and 2012.
Study procedure
Respondents participated in individual, face-to-face, un-
structured, and in-depth interviews that lasted approxi-
mately 60–90 min and were conducted by interviewers
(MG/MS), who had gathered previous experience in
one-on-one qualitative procedures, as well as in treatment
of substance-abusing individuals. Participation was volun-
tary and compensation of 5 Swiss Francs was offered, ei-
ther in the form of a cash payment (in the outpatient
setting) or as a gift card for the same amount (in the in-
patient setting). All participants were informed of their
right to end the interview at any time if they wished to. In
accordance with recommended principles of conducting
qualitative research, the interview began with narrative
opening questions, but our topic guide provided a flexible
interview framework to explore beliefs that were not
spontaneously covered in participants’ initial narratives.
We were careful to ask open-ended and neutrally
worded questions to avoid eliciting socially desirable
responses. Additionally, appropriate non-judgmental
and non-leading probes (echo probe, “uh-huh” probe,
“tell-me-more” probe) were used during the interviews
to explore perceptions that were not covered spontan-
eously in patients’ initial narratives. Finally, we used
summarizing prompts to ensure that participants’
meaning had been accurately depicted, especially in re-
gard to their views on a BZD maintenance or substitu-
tion treatment approach.
Ethics
The research protocol was reviewed and approved by
Zurich’s cantonal ethics committee. All participants
were assured confidentiality and provided their written, in-
formed consent, specifically to the digital recordings of
the interviews. Identifying information was removed from
the transcript, which were then assigned a code number.
Data management and analysis
Data collection and analyses were conducted simultan-
eously until saturation had been reached. All interviews
were digitally recorded, using dictamus for iOS, and then
transcribed verbatim. Transcripts were compared with
the recordings by the research team and validated with
patients, if necessary.
Mayring’s qualitative content analysis approach was
used to evaluate findings. This framework constitutes a
controlled approach for empirical and methodological
qualitative analysis of texts within their context of com-
munication, following content analytical rules and step-
by-step models, without rash quantification [27]. Mate-
rials were coded using an inductive qualitative procedure
[28], and the research team (ML, AB, MG, CC) held bi-
weekly discussions on the categories that were obtained
to validate ratings and achieve consensus. ML applied
the final code, with confirmation of consistency through
blind dual coding of transcripts with MG and CC.
Results
Table 1 presents self-reported benzodiazepine consump-
tion patterns, mental health problems, treatment behav-
iors, and attitude towards a benzodiazepine maintenance
approach. Our 41 study participants had a mean age of
39.5 years ± SD 9.2 (median 39.0 years, range 21 to
65 years).
In this explorative study, participants often used the
term “substitution” in their initial narrative, primarily
while referring to the substitution of benzodiazepines for
other psychotropic substances like alcohol or heroin.
The statement of VP22 exemplifies this perception:
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“…Initially I took mostly heroin and when I wanted to
sleep I just waited until the flash wore off. But when I
could not fall asleep this way, then I thought, instead
of taking more Heroin, I take a benzodiazepine, then I
did not just save money, but it also helped better to
fall asleep. O.k. with heroin you can also fall asleep,
but actually out of cost considerations I switched over
to benzodiazepines...”
VP 22, male, 46 years
Furthermore, participants associated “substitution” with
the replacement of BZDs with a non-BZD class of agents
such as antipsychotics or antidepressants, which was some-
thing they had often experienced during treatment. In
addition, some participants described a long-term BZD
maintenance approach with a slow-onset, long-acting BZD,
when referring to previous experiences and preferences for
different kinds of BZDs. Only few participants had heard of
a “maintenance” approach by their treating physicians,
reflecting the heterogeneity of this sample in regard to
treatment duration (weeks to years) and form of interven-
tion, ranging from abstinence-oriented benzodiazepine
Table 1 Self-reported benzodiazepine consumption patterns,
mental health problems, treatment behaviors, and attitude
towards a benzodiazepine maintenance approach
Number Percent





Under 5 years 14 34.1




Could not recall 1 2.4
Age at initial benzodiazepine use
Under 25 years 15 36.6
25 to 40 years 18 43.9
Over 40 years 7 17.1
Could not recall 1 2.4
Maximum dosage of a
benzodiazepine that were ever
used (expressed in diazepam
equivalents)
Under 50 mg 14 34.1






Less than 1 1 2.4
1 to 3 24 58.8
4 to 9 9 22.0
More than 9 7 17.0
Number of comorbid psychiatric




More than one 16 39.0
Comorbid psychiatric diagnosis
groups except substance use
disorders (ICD-10)
Schizophrenia 1 2.4







Table 1 Self-reported benzodiazepine consumption patterns,
mental health problems, treatment behaviors, and attitude
towards a benzodiazepine maintenance approach (Continued)











Employment status at the
time of interview
Employed 12 29.3





No data 1 2.4
Attitude towards an benzodiazepine
maintenance approach




No data 4 9.7
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discontinuation approach to the more permanent prescrip-
tion of slow-onset, long-acting BZDs.
Perceptions and beliefs about an agonist treatment (or
“maintenance”) approach had to be elucidated using
non-judgmental questions: “How would you feel about a
substitution for benzodiazepines? Like, for example, heroin,
that gets substituted with methadone?” Furthermore and in
cases of highly knowledgeable participants, we gave more
specific examples for slow-onset, long-acting benzodiaze-
pines usually by mentioning specific brand names.
However, participants’ statements in regard to such a
treatment strategy sometimes appeared to contradict their
previous statements or explanations. Although we tried to
clarify apparent inconsistencies using additional probes,
they persisted in four instances:
“…For me, personally, that is nothing…I think that is a
stupid question, but with heroin you have, but I never
tried heroin, as far as I know you have a “high.” And
that is something you don’t have with methadone. The
“high” feeling is removed with methadone—it just eases
withdrawal effects…And benzodiazepines do not make
a “high,” so there is no “high” feeling, at least not with
me…so I would not take (substituting drugs) since I
don’t have side effects from benzodiazepines…if
someone just overcomes feelings of anxiety and then
does not need benzos anymore, then I think it is good,
if there is such a development…but I am very happy
that they are around...”
VP6, male, 30 years
One participant complained of a headache upon reaching
this topic and ended the interview. But the majority of our
41 participants discussed their beliefs and assumptions on
this topic, allowing us to identify several common themes.
Some overlap occurred between identified themes; however,
no category applied to all participants. In comparison to
high-dose-dependent patients’ beliefs surrounding reasons
for use and experiences of withdrawal, participants tended
to have rather “strong” opinions on this subject that could
be subsumed into three themes:
Theme I: maintenance treatment—“Only if I can try to
discontinue…and please don’t call it that!”
Surprisingly, in this sample of long-term and high-dose
BZD-dependent participants who had undergone multiple
BZD withdrawal attempts, frequent relapse, and hospital
re-entries, most were ambivalent about a maintenance
treatment approach with slow-onset, long-acting BZDs.
While they could envision the regular intake of a prescribed
BZD on a long-term basis, it became clear that they were
convinced that discontinuation treatment was the right
treatment strategy for them.
“…I know which route I want to take… I want to zero,
with both Valium→ (diazepam) and methadone… I am
committed to withdrawal, no matter what happens...”
VP6, male, 30 years
“…But what I started to realize during this stay (in the
hospital) is that I actually increase my dosage…
Initially I want to reduce the dosage and then I want
to see how that goes, but I have the goal that in the
sometime in the future I can live without prescribed
drugs. At least without benzodiazepines....”
VP04, female, 35 years
These views were often influenced by what participants per-
ceived as their physician’s advice. However, even participants
who were skeptical about a BZD maintenance approach felt
that long-term prescriptions from their physicians for BZDs
were fine as long as they could continue to focus on discon-
tinuation in the future. They were more open towards
substitution treatment with non-BZD alternatives, al-
though many immediately pointed out perceived short-
comings of neuroleptic medications and antidepressants.
“…Then I would be dependent on something. Not of a
benzo but of a benzo substitute…No, no, I think that is
out of the question. Maybe during reduction, and
one-two weeks after that, here and there a Remeron→
(mirtazapine)…Short treatment with Seroquel→
(quetiapine), if you cannot find sleep or you are
nervous, that is O.K. An antipsychotic has just not the
same potency like a benzodiazepine. Short-time treat-
ment, I like, yes…but more long-term, probably not...”
VP25, male, 32 years
“…I get a headache from that (Seroquel→ (quetiapine)).
As a benzodiazepine substitution, it is nothing for me.
Maybe to relieve craving for half an hour, but not as a
benzo substitute...”
VP37, female, 24 years
A considerable margin of participants who were in-
volved in an opioid maintenance treatment at the time
of the interview were equally hesitant to embrace a BZD
maintenance strategy, since they felt it would limit their
freedom of movement.
“…ahmm, I already made that mistake with methadone...”
VP05, male, 32 years
Theme II: maintenance treatment—“More stability and
less criminal activity…and that is why I would try it.”
Although some participants viewed an agonist maintenance
treatment approach rather cautiously, the vast majority
spontaneously, and without further probing, described
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the possible advantages of such a strategy. Almost all
had had tried (either by legal or illegal means) different
BZDs with diverse pharmacokinetic properties and
therefore relied on their own experiences and percep-
tions when making assertions, and they believed that a
maintenance intervention with a slow-onset and long-
acting BZD such as Xanax retard→ (alprazolam), or
Rivotril→ (clonazepam), provided them with more stabil-
ity. For example, it would allow them to take a BZD once
daily, instead of several times per day.
“…Valium→ (diazepam) has a constant level, It does
not go up and down like Temesta→ (lorazepam)…
Valium→ (diazepam) has a longer half-life, so I do
not have to take it several times a day…My psychiatrist
told me that I might just never make it to completely
zero…If anxiety and panic attacks return, then I will just
have to continue to take the medicine… For me, it is
just important to take as little as possible, so that my
short-term memory is not getting any worse and it does
not turn into Alzheimer...”
VP17, male, 45 years
“…Because you can use Valium→ (diazepam) as a
drug that creates a level. With me, it is about that I
can’t turn off at night, that I can’t sleep. I am working
as electrical engineer and I was also working in the
sleep, looking for solutions and finding them…My
psychiatrist told me that I must get away from benzos.
They have increased my dosage of
Depakine→ (valproatic acid) and since then I just
have problems. Your life quality starts suffering. I
don’t feel anything, my libido is less...”
VP39, male, 40 years
Some participants reported they had experimented
with different kinds of BZDs and felt the ones that lasted
longer were the most beneficial to them; this had changed
their preferences and consumption patterns.
“…Seresta→ (oxazepam) was the only benzo
where I did not have this paradox effects
(compared to Rohypnol→ (flunitrazepam) and
Dormicum→ (midazolam)). It takes anxiety…it did
not have euphoric effects on me…meanwhile, I am at
the point at which I notice that Seresta→ (oxazepam)
in a certain dosage keeps me from consuming
stronger BZDs. In any way I need to take it, in
just a little higher dosage, that I do not have the
craving for Dormicum→ (midazolam)…I took
Seresta→ (oxazepam) solely for half a year, a year,
but then I reduced it. It protected me from using
Dormicum→ (midazolam)...”
VP31, male, 43 years
“…At the moment, this is right for me (Xanax
retard→, alprazolam). I do not feel craving. But I do
not know how it is if I have no benzo at all, if then
the lust after Dormicum→ (midazolam) would return.
But at the moment, I somehow do not have a desire
for benzodiazepines...”
VP02, male, 38 years
Interestingly, some participants had talked to their
physicians about taking longer-lasting BZDs in a regu-
lated setting, but had received mixed responses.
“…My physician always told me that I should find
another doctor a pharmacy that gives it to me (on a
daily basis). You go there, frequently, get your dosage.
Today, eight; tomorrow, eight. Not for a week,
because it is so difficult to manage. I hide that stuff so
carefully that I could not find it anymore, a supply for
a week…This is all crap… There was just never a
possibility in Zurich to get this stuff prescribed.
Although I must have addressed this issue a hundred
times…well, back to the benzodiazepines, if you
should substitute them, then in a little pharmacy,
where you will daily get what you need. A realistic
amount for people who are dependent and something
long-term to cover you...”
VP34, male, 31 years
Another widely held belief among the participants of
this study was that long-term maintenance for dependent
individuals would result in a closure of the black market,
reduce criminality, and enable individuals to stay away
from the “street.”
“…I mean I see it on the street every day—so many
people are hunting after this crap. I mean then the
pressure would be gone if you could get it from a
doctor...”
VP02, male, 38 years
“…you should see what is going on in the
Langsstrasse on Sunday, every Sunday, when most
pharmacies are shut down and then there are too few
benzos…and then people come from the Aargau...”
VP24, female, 22 years
Theme III: maintenance treatment—“No cure, no brain
and no flash…and thus just for everybody else”
Consensus among the more skeptical participants was that
a BZD maintenance approach would leave them dependent
on a psychotropic substance and would therefore have a
major impact on their individual decision-making about
such a treatment strategy.
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“…It is just the same. It would make you addicted…
you are still in the same dependency…it needed to be
something that I could use in high doses and still
leave me fit…if something like this would be in
existence, it would certainly mash your brain...”
VP07, male, 41 years
“…I still would have the feeling that I am dependent
on benzodiazepines…but I think (a substitution) could
be very beneficial for other patients...”
VP12, female, 66 years
Subjects also indicated that they were concerned about
long-term cognitive impairments, especially in light of
what they perceived to have heard from their treating
physicians; they therefore wanted more scientific data.
“…I want to live without such a substance. My
physician outside always tells me that, that you will
get dementia, if you take this medicine too long...”
VP29, male, 50 years
“…(My physician) warned me about it. I should be careful.
This stuff makes you dependent and forgetful. I should
rather drink one or two beers in the evening, instead of
taking so much medicine. Out of my perspective he is
right, why should I be taking so much medicine?...”
VP19, male, 33 years
Some participants expressed concern about possible
interactions with concurrent somatic medications and
therefore found any potential benefit difficult to assess.
“…It needs to be compatible with my HIV drugs...”
VP31, male, 43 years
Contrary to a priori expectations, some high-dose-
dependent patients who were abusing short-acting and
fast-onset BZDs felt uncomfortable about a long-term
maintenance approach with a slow-onset, long-acting
BZD because they were seeking a euphoric “high” and
were afraid that maintenance would make this impossible.
“…This is what I have right now with Valium
® (diazepam). It is really stupid because it does not
kick. I cannot inject anything. It is not a drug. Valium
® (diazepam) is a medicine, for me. And Dormicum
® (midazolam) is a drug. A drug has to kick in and a
medicine is supposed to cover something...”
VP24, female, 22 years
“…I get Valium ® (diazepam) as a substitute. It is not
the same because I am an injecting user and not
someone who swallows tablets. I am an injecting
tablet user. You just don't get a benzo withdrawal,
but it is not this most beautiful and amazingly
wonderful blue tablet that so nicely kicks in, it is
just Valium ® (diazepam)…that I only take in an
emergency, because Dormicum ® (midazolam) is the
absolute greatest of all medicine...”
VP24, female, 22 years
Virtually, all participants believed that a maintenance
strategy was important and worth suggesting to individ-
uals they knew and perceived as highly dependent.
“…A substitution for benzos…hmm…that would be
useful for people who always try and always fail and
who then say they do not want that anymore. For
those, it would be reasonable...”
VP27, female, 36 years
Discussion
This explorative narrative study investigated patient per-
ceptions and views of discontinuation treatment as well
as a BZD maintenance or substitution treatment strategy.
Generally, the results suggest that patients with a high-dose
BZD dependence who had undertaken multiple attempts at
withdrawal, in inpatient as well as outpatient settings, fa-
vored a discontinuation treatment approach with complete
abstinence from BZDs as its aim, despite experiencing fre-
quent relapse. A maintenance treatment approach with
continued prescription of a slow-onset, long-acting agonist
was perceived ambivalently, ranging from positive and
welcoming attitudes to caution and even rejection. These
findings among a sample of high-dose-dependent BZD
users, with and without a comorbid opioid dependence,
align with two reports about BZD-dependent patients cur-
rently in opioid maintenance treatment. One of these
studies reported that 71 % of current BZD users intended
to stop BZD use completely, or at least wanted to try to
[29]. The other found that even patients who experience
frequent detoxification failure were difficult to attract to a
trial using a BZD maintenance approach [15].
We also found that participants associated the use of
slow-onset, long-acting BZDs with an increase in per-
ceived stability, reduced illegal and criminal activity, less
craving for short-acting BZDs, and a change in their
consumption pattern of fast-onset, short-acting BZDs.
Especially, those not using BZDs solely for recreational
purposes developed a preference for BZDs with a slower
onset and a longer duration of action. The most import-
ant additional factor that drove their attitude towards
maintenance treatment was a perceived absence of a de-
finitive cure for BZD dependence. Side effects in the
form of cognitive impairments were less important to
participants, often driven by perceived warnings by
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physicians of an increased risk for the development of
(Alzheimer) dementia [30–33].
To our knowledge, this is the first study to use qualita-
tive methodology to explore high-dose BZD-dependent
patients’ attitudes towards an agonist treatment ap-
proach. While the clinical aspects are perceived as
beneficial, our findings suggest that participants’ moral
convictions about dependence, and their perceptions
about the beliefs of treating physicians [34], are particu-
larly contentious issues [35].
We found that almost all participants had used a
variety of BZDs, possessing diverse pharmacokinetic
properties, and described times when they had either
been adequately maintained by their physicians or had
become more stable by illegally switching to slow-onset,
long-acting BZDs with less irregularities. Recreational
users who preferred short-acting, fast-onset BZDs experi-
enced periods of lessened withdrawal and cravings.
We found that some high-dose-dependent users who
specifically looked for euphoric effects opposed a mainten-
ance approach because they feared and had experienced
that their sought-after BZD “flash” was eliminated when
they took slow-onset, long-acting BZDs. Interestingly,
some participants were aware of the beneficial effects of
slow-onset, long-acting BZDs and asked their physicians
to initiate a permanent and regulated BZD disposal, es-
sentially developing and implementing their own harm
reduction strategy. The more positive views of slow-onset,
long-acting BZDs among this sample of patients align with
previous reports on agonist treatment interventions
[15, 20], as well as with our own findings on the decreased
use of additional BZDs (refrainment from additional use in
27.1 %). It also aligns with the improvement in clinical de-
pression in patients, found by therapists (improvement in
56.3 %) who switched 48 opioid-dependent patients in opi-
oid maintenance treatment and who had a co-occurring
high-dose BZD dependence to clonazepam [36].
Patients’ skepticism of long-term pharmaceutical treat-
ment interventions for chronic disorders is common across
many medical fields, even when scientific evidence shows
its effectiveness. For example, a survey of 2061 patients
with type 2 diabetes who were not enrolled in insulin treat-
ment found that they perceived the clinical efficacy of insu-
lin as low and would blame themselves if they had to begin
insulin therapy [37]. Similar findings have been reported in
studies investigating individuals with hypertension who
were non-adherent to antihypertensive medications: some
33 % stopped the use because they “did not like taking
medications” [38]. Unfavorable attitudes towards long-term
pharmaceutical interventions are even more apparent
in a substance-abusing population. Despite OMTs’ proven
effectiveness in reducing harm [39–41], a recent quali-
tative study investigating barriers to treatment entry for
opioid-dependent users found, among other factors,
that some patients were apprehensive about a long-term
maintenance program and preferred a time-limited
program and a discontinuation approach [42]. Other
barriers—identified in the same study—included “real
or rumored side effects, fear of withdrawal during in-
carceration or disinterest in adherence to the structure
of treatment programs”—especially the last aspect may
have, although not specifically mentioned, contributed
to the unfavorable perception of some participants to-
wards benzodiazepine maintenance treatment as well. In
this context, it needs to be pointed out that 61 % of our
participants had past or current experiences with OMT
and may therefore have intuitively drawn parallels to such
programs and their restrictions (e.g., limitations on take
home dosages).
Although the comparison of BZD maintenance to an
opioid maintenance treatment approach is not entirely
accurate (since patients in OMT do not exhibit cognitive
impairments, and side effects related to cognition and
memory are one of the major limitations of a BZD agon-
ist substitution approach [43, 44]), our explorative study
shows that some high-dose BZD-dependent patients
may require an alternative to a discontinuation treatment
approach. While we acknowledge the possible negative
consequences of such an approach, especially in individuals
using multiple substances [45], we suggest that clinicians
consider our findings in the context of the large group of
patients who fail in abstinence-oriented treatments. We
urge them to provide—or develop—some alternative guid-
ance when they are contacted by patients who want to
change their BZD consumption pattern but find themselves
unable to successfully complete discontinuation programs.
We used an unstructured, topic-guided approach in
line with recommendations for the use of qualitative
methodology to explore patient perceptions, since little
is known about this clinical subject and a semi-structured,
interview-guided approach was not feasible. Although pa-
tients frequently spontaneously addressed substitution or
maintenance in their initial narratives, we used some ques-
tions that contained an analogy to the treatment of heroin
dependence in order to elucidate participants’ beliefs. It is
possible that this could have led some of them to express
unfavorable beliefs, since heroin users are a heavily stigma-
tized patient group. However, we believe that we can report
saturated data, since we continued interviewing until no
new themes emerged and all categories had been tested for
disconfirming case variations.
Questions about conceptual generalizability also arise,
since this study was conducted with 41 long-term, high-
dose-dependent patients, the majority of whom were in
inpatient treatment at the time of the interview and might
therefore have preferred a discontinuation approach.
However, participants who were recruited in the out-
patient settings expressed similar views. An additional
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consideration is that 19 potential participants declined
inclusion, so we are likely to have missed the personal
views of individuals who felt especially sensitive about
being interviewed on their BZD dependence. Although
the interviews were conducted outside the treatment
setting and subjects were informed that no information
except suicidal ideation would be made available to
the treating physicians, some participants might have
responded with answers (especially in regard to their
current discontinuation therapy) that they believed
were being sought by the interviewer. While we acknow-
ledge these limitations, we believe that this study adds to
the scarce literature on the beliefs of long-term, high-dose
BZD-dependent individuals with a diverse clinical (past
treatment experience, comorbidity, gender) and socio-
economic background (occupational status). Finally, the
generalizability of our sample remains to be established as
patients in our sample were recruited in a clinical context.
The inclusion of individuals who are out of treatment
would help us better understand how well our findings
may apply to this population.
Conclusions
We conclude that patients with a high-dose BZD depend-
ence are generally in favor of a discontinuation treatment
approach, despite treatment failure, because they view a
maintenance treatment approach (with continuous prescrip-
tion of a slow-onset long-acting agonist) ambivalently. We
identified three overlapping themes that summarized pa-
tients’ perceptions on maintenance treatment: (1) “Only if I
can try to discontinue…and please don’t call it that!” (2)
“More stability and less criminal activity…and that is why I
would try it.” and, finally, (3) “No cure, no brain and no
flash…and thus just for everybody else.” Since some patients
had experienced a slow-onset, long-acting BZD as stabilizing
and having helped them abstain from fast-onset, slow-acting
BZDs and from criminal activity, we encourage the consid-
eration of treatment alternatives if discontinuation strat-
egies fail. Future research needs to address the important
clinical questions of side effects, focusing on the extent of
cognitive impairments in a BZD-maintained population.
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